{"entity":{"id":"jnj-90301900","kind":"drug","name":"JNJ-90301900","aka":["JNJ-90301900 (NBTXR3)","NBTXR3"],"tldr":"JNJ-90301900 is an experimental radioenhancer nanoparticle from Johnson & Johnson Enterprise Innovation in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.","summary":"JNJ-90301900 is a radioenhancer nanoparticle developed by Johnson & Johnson Enterprise Innovation. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: A suspension of inert, crystalline hafnium oxide nanoparticles designed to generate oxygen free radicals that destroy cancer cells once activated by ionising radiation. ClinicalTrials.gov describes the intervention as: Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04892173 (JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC), in head and neck squamous cell carcinoma. The largest, NCT04892173, plans to enrol 500 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of JNJ-90301900","url":"https://clinicaltrials.gov/search?intr=JNJ-90301900"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04892173","nct06667908"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"radioenhancer nanoparticle","mechanism":"A suspension of inert, crystalline hafnium oxide nanoparticles designed to generate oxygen free radicals that destroy cancer cells once activated by ionising radiation.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jnj-90301900/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}],"trial":[{"id":"nct06667908","kind":"trial","name":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667908/"},{"id":"nct04892173","kind":"trial","name":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","route":"/trials/nct04892173/"},{"id":"nct07224152","kind":"trial","name":"NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer","route":"/trials/nct07224152/"}]}}